OnCo

Trabectedin

Checked 2026-09-09

Liposarcoma and leiomyosarcoma after an anthracycline

One cycle

every 21 days
178141521Trabectedin: 1.5 mg/m² through a central line, IntravenousTrabectedin
21-day cycle, until progressionIntravenous Continuous infusion

Components

DrugDoseRouteDays
Trabectedin
Cytotoxic (DNA minor-groove binder)
1.5 mg/m² through a central lineIVD1 (24 h infusion)
Cycles
until progression
21-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine

Notes

  • Dexamethasone 20 mg IV 30 minutes before each dose reduces hepatotoxicity.

Used in

Source

Demetri, JCO 2016

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers